Evidence map›Paper›PMID 41752145›Full record

ReviewInternational journal of molecular sciences2026

The Role of CRISPR and Its Therapeutic Applications in Glioblastoma.

Salma Fayed, Salma Amer, Malak Badawy, Lara Bou Malhab, Nourhan Omran, Ghalia Khoder, Rose Ghemrawi, Mohamed Haider, Rifat Hamoudi, Rania Harati

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Salma FayedDepartment of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates.
Salma AmerDepartment of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates.
Malak BadawyDepartment of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates.
Lara Bou MalhabResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates.
Nourhan OmranDepartment of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates.
Ghalia KhoderResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates.ORCID 0000-0002-6036-1022
Rose GhemrawiCollege of Pharmacy, Al Ain University, Abu Dhabi P.O. Box 64141, United Arab Emirates.ORCID 0000-0002-2465-0812
Mohamed HaiderResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates.ORCID 0000-0003-3150-9275
Rifat HamoudiResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates.ORCID 0000-0002-1402-0868
Rania HaratiDepartment of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates.ORCID 0000-0001-6672-2944

Funding

ASPIRE Precision Medicine Research Institute Abu Dhabi VRI-20-10University of Sharjah 210111350University of Sharjah 2201110368University of Sharjah 23010902146
6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) remains the most aggressive and treatment-refractory form of primary brain tumor in adults, characterized by rapid proliferation, intratumoral heterogeneity and resistance to current therapies. Despite therapeutic advancements in surgical resection, radiotherapy and chemotherapy, clinical outcomes remain poor, underscoring the need for innovative molecular strategies. This review examines the therapeutic potential of CRISPR/Cas9 genome-editing technologies in GBM, highlighting their ability to model, dissect and potentially correct the genetic alterations that drive GBM tumorigenesis. Key molecular targets, such as

Indexed as

Brain NeoplasmsCRISPR-Cas SystemsGene EditingGenetic TherapyGlioblastomaAnimalsHumansblood–brain barrierCRISPR/Cas9 genome editinggene editing delivery vectorsglioblastoma multiforme (GBM)

Identifiers

PMID41752145
PMCPMC12940740

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.